185 related articles for article (PubMed ID: 20977419)
1. Glucocorticoid's pharmacology: past, present and future.
Gessi S; Merighi S; Borea PA
Curr Pharm Des; 2010; 16(32):3540-53. PubMed ID: 20977419
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists.
Stahn C; Löwenberg M; Hommes DW; Buttgereit F
Mol Cell Endocrinol; 2007 Sep; 275(1-2):71-8. PubMed ID: 17630118
[TBL] [Abstract][Full Text] [Related]
3. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands.
Löwenberg M; Stahn C; Hommes DW; Buttgereit F
Steroids; 2008 Oct; 73(9-10):1025-9. PubMed ID: 18221974
[TBL] [Abstract][Full Text] [Related]
4. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index.
Schäcke H; Berger M; Rehwinkel H; Asadullah K
Mol Cell Endocrinol; 2007 Sep; 275(1-2):109-17. PubMed ID: 17630119
[TBL] [Abstract][Full Text] [Related]
5. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects.
Schäcke H; Schottelius A; Döcke WD; Strehlke P; Jaroch S; Schmees N; Rehwinkel H; Hennekes H; Asadullah K
Proc Natl Acad Sci U S A; 2004 Jan; 101(1):227-32. PubMed ID: 14694204
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms involved in the side effects of glucocorticoids.
Schäcke H; Döcke WD; Asadullah K
Pharmacol Ther; 2002 Oct; 96(1):23-43. PubMed ID: 12441176
[TBL] [Abstract][Full Text] [Related]
7. [New developments in glucocorticoid therapy: selective glucocorticoid receptor agonists, nitrosteroids and liposomal glucocorticoids].
Huisman AM; Jacobs JW; Buttgereit F; Bijlsma JW
Ned Tijdschr Geneeskd; 2006 Mar; 150(9):476-80. PubMed ID: 16553045
[TBL] [Abstract][Full Text] [Related]
8. Targeting glucocorticoid side effects: selective glucocorticoid receptor modulator or glucocorticoid-induced leucine zipper? A perspective.
Ayroldi E; Macchiarulo A; Riccardi C
FASEB J; 2014 Dec; 28(12):5055-70. PubMed ID: 25205742
[TBL] [Abstract][Full Text] [Related]
9. Selective glucocorticoid receptor modulation: New directions with non-steroidal scaffolds.
Sundahl N; Bridelance J; Libert C; De Bosscher K; Beck IM
Pharmacol Ther; 2015 Aug; 152():28-41. PubMed ID: 25958032
[TBL] [Abstract][Full Text] [Related]
10. [Current insights into the development of new glucocorticoid receptor ligands].
Buttgereit F; Song IH; Straub RH; Burmester GR
Z Rheumatol; 2005 Apr; 64(3):170-6. PubMed ID: 15868334
[TBL] [Abstract][Full Text] [Related]
11. SEGRAs: a novel class of anti-inflammatory compounds.
Schäcke H; Hennekes H; Schottelius A; Jaroch S; Lehmann M; Schmees N; Rehwinkel H; Asadullah K
Ernst Schering Res Found Workshop; 2002; (40):357-71. PubMed ID: 12355726
[TBL] [Abstract][Full Text] [Related]
12. Optimized glucocorticoid therapy: teaching old drugs new tricks.
Strehl C; Buttgereit F
Mol Cell Endocrinol; 2013 Nov; 380(1-2):32-40. PubMed ID: 23403055
[TBL] [Abstract][Full Text] [Related]
13. Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor?
Newton R; Holden NS
Mol Pharmacol; 2007 Oct; 72(4):799-809. PubMed ID: 17622575
[TBL] [Abstract][Full Text] [Related]
14. Genomic and nongenomic effects of glucocorticoids.
Stahn C; Buttgereit F
Nat Clin Pract Rheumatol; 2008 Oct; 4(10):525-33. PubMed ID: 18762788
[TBL] [Abstract][Full Text] [Related]
15. New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation.
Vandevyver S; Dejager L; Tuckermann J; Libert C
Endocrinology; 2013 Mar; 154(3):993-1007. PubMed ID: 23384835
[TBL] [Abstract][Full Text] [Related]
16. Discovery of New non-steroidal selective glucocorticoid receptor agonists.
Potamitis C; Siakouli D; Papavasileiou KD; Boulaka A; Ganou V; Roussaki M; Calogeropoulou T; Zoumpoulakis P; Alexis MN; Zervou M; Mitsiou DJ
J Steroid Biochem Mol Biol; 2019 Feb; 186():142-153. PubMed ID: 30321666
[TBL] [Abstract][Full Text] [Related]
17. The glucocorticoid receptor agonistic modulators CpdX and CpdX-D3 do not generate the debilitating effects of synthetic glucocorticoids.
Hua G; Zein N; Paulen L; Chambon P
Proc Natl Acad Sci U S A; 2019 Jul; 116(28):14200-14209. PubMed ID: 31221758
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung diseases.
Newton R; Leigh R; Giembycz MA
Pharmacol Ther; 2010 Feb; 125(2):286-327. PubMed ID: 19932713
[TBL] [Abstract][Full Text] [Related]
19. New insights into the novel anti-inflammatory mode of action of glucocorticoids.
Ingawale DK; Mandlik SK
Immunopharmacol Immunotoxicol; 2020 Apr; 42(2):59-73. PubMed ID: 32070175
[TBL] [Abstract][Full Text] [Related]
20. Non-genomic Effects of Glucocorticoids: An Updated View.
Panettieri RA; Schaafsma D; Amrani Y; Koziol-White C; Ostrom R; Tliba O
Trends Pharmacol Sci; 2019 Jan; 40(1):38-49. PubMed ID: 30497693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
